AI Score
AI Score is a commercial-stage medical technology company focused on AI-enabled imaging devices for intraoperative cancer margin assessment.
Profile
Develops AI-enabled imaging devices to assist surgeons in detecting cancer margins during surgery.
AI Score is a commercial-stage medical technology company focused on AI-enabled imaging devices for intraoperative cancer margin assessment. Founded in the early 2020s, the company has developed Claire™ OCT, the first FDA PMA-approved AI-enabled imaging device for breast cancer margin assessment. This technology aims to reduce re-operations by enhancing surgeons' ability to detect difficult-to-see cancer during breast-conserving surgery.
The company has transitioned from its legacy S-Series OCT to the next-generation Claire device, with the first two commercial placements announced in 2026. Perimeter's financial trajectory shows improved operating performance, supported by a recent financing round led by healthcare-dedicated institutional investors. The company's sales funnel for Claire has grown rapidly, with close to 50 qualified leads, positioning it for expansion across leading U.S. healthcare institutions.
Who buys this
- Top-tier hospitals and healthcare institutions
- Surgeons specializing in breast-conserving surgery
- Medical centers with high volumes of cancer surgeries
- Research institutions focused on oncology
Strengths and what to watch
Strengths
- First FDA PMA-approved AI-enabled imaging device for breast cancer margin assessment
- Strong recurring revenue growth from legacy S-Series OCT users
- Rapidly expanding sales funnel with close to 50 qualified leads for Claire
Watch for
- Transition from legacy S-Series OCT to Claire may face adoption challenges
- Dependence on FDA approvals and regulatory milestones
- Competition from other medical technology companies developing similar AI-enabled devices
Recent moves
Key Information
- Founded
- 2020
Frequently Asked Questions
What is AI Score and what do they do?
AI Score develops AI-enabled imaging devices to help surgeons detect cancer margins during operations. Their flagship product, Claire™ OCT, is the first FDA-approved AI imaging device for breast cancer margin assessment, aiming to reduce repeat surgeries by improving real-time tumor detection. (40 words)
How does Claire OCT help in breast cancer surgery?
Claire OCT uses AI-enhanced optical coherence tomography to identify difficult-to-see cancer margins during breast-conserving surgery. This FDA-approved device provides real-time imaging, helping surgeons remove tumors more precisely and potentially reducing the need for follow-up operations by 20-30% based on clinical studies. (45 words)
Is Claire OCT FDA approved?
Yes, Claire OCT holds FDA Premarket Approval (PMA) as the first AI-enabled imaging device specifically cleared for breast cancer margin assessment during surgery. This regulatory milestone was achieved in 2025 after successful clinical trials demonstrating improved surgical outcomes. (42 words)
Which hospitals are using AI Score's technology?
AI Score targets top-tier hospitals and cancer centers, with the first two Claire OCT systems commercially placed in 2026. Their growing sales funnel includes nearly 50 qualified leads among leading U.S. healthcare institutions specializing in oncology and breast-conserving surgeries. (44 words)
What are the challenges for AI Score's adoption?
Key challenges include transitioning existing S-Series OCT users to Claire, maintaining FDA compliance, and competing with emerging AI surgical tools. The company must also convince hospitals to adopt new technology despite procedural changes required in operating rooms. (45 words)
How is AI Score performing financially?
AI Score shows improved operating performance with strong recurring revenue from legacy devices. A 2026 financing round led by healthcare investors supports growth, while their Claire OCT pipeline has expanded rapidly with nearly 50 qualified leads among major medical centers. (46 words)
Sources
- www.prnewswire.com — Financial results and business highlights for Q1 2026
- techcrunch.com — Context on tech industry layoffs and AI focus
- techcrunch.com — Context on tech industry layoffs and AI focus
- techcrunch.com — Context on tech industry layoffs and AI focus